3-ethynyl-4-methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)benzamide

This compound is a pharmaceutical intermediate used in the synthesis of ponatinib, a targeted cancer therapy. It is a benzamide derivative containing an ethynyl group, a trifluoromethyl-substituted aromatic ring, and a piperazine moiety.